Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has released revolutionary proof-of-concept data demonstrating the potential therapeutic cognitive effects of its experimental drug, HT-ALZ, in an Alzheimer’s disease mouse model. After chronic oral dosing of HT-ALZ at 20mg/kg and 40mg/kg, cognitive and behavioral assessments revealed promising results. This research was conducted under a Sponsored Research Agreement with Washington University in St. Louis and HT-ALZ is a therapeutic candidate in development under the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer’s disease. These results are a breakthrough in the fight against Alzheimer’s, paving the way for a new therapeutic option for those afflicted with the devastating disease.
The water maze and elevated plus maze tests have revealed that longer treatment using doses of 20mg/kg and 40mg/kg of HT-ALZ can have a positive effect on the performance and anxiety-like behavior of mice. Particularly impressive results have been found in the water maze, where the 20mg group already showed significant improvements in spatial memory. The elevated plus maze test is an effective measure of anxiety-like behavior, taking into account a mouse’s natural aversion to open and elevated areas, as well as its exploratory behavior in novel environments.
Hoth’s groundbreaking study showed that a single dose of HT-ALZ, an orally administered drug, had a striking effect in reducing the concentration of amyloid β (Aβ) plaques in the brain interstitial fluid of Alzheimer’s Disease mice (aged APP/PS1+/-). This striking decrease was observed in both male and female mice, compared to the placebo-treated animals and previous baseline Aβ levels. These findings provide hope for a potential treatment for the devastating effects of this neurodegenerative disease.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize patient care with groundbreaking treatments that improve quality of life. We utilize a patient-centric approach and collaborate with a team of scientists, clinicians, and key opinion leaders to identify and investigate therapies that could make a real difference. From the bench to pre-clinical and clinical testing, we are a catalyst in early-stage pharmaceutical research and development, striving to make a positive impact on the lives of those we serve.